Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

ATNM Actinium Pharmaceuticals Inc

1,90

0,03 (1,60%)

28 Mar 2025 - Fermé

Retardé de 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

Plus de graphiques de la Bourse Actinium Pharmaceuticals

Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025

Plus de graphiques de la Bourse Actinium Pharmaceuticals

Actualités Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Jeudi 27 Mars 2025 ( il y a 18 heures) • PR Newswire (US)

Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
Jeudi 27 Mars 2025 ( il y a 19 heures) • PR Newswire (US)

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
Mercredi 26 Mars 2025 ( il y a 2 jours) • PR Newswire (US)

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
Mardi 25 Mars 2025 ( il y a 3 jours) • PR Newswire (US)

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
Lundi 24 Mars 2025 ( il y a 3 jours) • PR Newswire (US)

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
Jeudi 20 Mars 2025 ( il y a 1 semaine) • PR Newswire (US)

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical D
Mercredi 19 Mars 2025 ( il y a 1 semaine) • PR Newswire (US)

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
Mardi 18 Mars 2025 ( il y a 1 semaine) • PR Newswire (US)

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Lundi 17 Mars 2025 ( il y a 2 semaines) • PR Newswire (US)

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Mercredi 12 Mars 2025 ( il y a 2 semaines) • PR Newswire (US)

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Mardi 11 Mars 2025 ( il y a 2 semaines) • PR Newswire (US)

Form 8-K - Current report
Mercredi 27 Novembre 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Plus d'articles sur Actinium Pharmaceuticals Inc

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales